Progestin action and progesterone receptor structure in human breast cancer: a review.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000345:Affinity Labels; D000818:Animals; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000473:pathology; D002478:Cells, Cultured; D002645:Chickens; D002848:Chromatography, DEAE-Cellulose; D004963:Estrenes / Q000494:pharmacology; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D015735:Mifepristone; D008970:Molecular Weight; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D010057:Oviducts / Q000032:analysis; D011372:Progestins / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011972:Receptor, Insulin / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011965:Receptors, Glucocorticoid / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis* / Q000187:drug effects
D000345:Affinity Labels; D000911:Antibodies, Monoclonal; D004963:Estrenes; D011372:Progestins; D011960:Receptors, Estrogen; D011965:Receptors, Glucocorticoid; D011980:Receptors, Progesterone; D015735:Mifepristone; D015127:9,10-Dimethyl-1,2-benzanthracene; D011972:Receptor, Insulin